Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
Conclusions and Relevance Trastuzumab rezetecan provided significant progression-free survival benefit over physician’s choice of chemotherapy in patients with ERBB2-low advanced breast cancer, with benefit observed across all key subgroups.
Appeared: Sunday, October 25. JAMA. Peer-reviewed journal.